课题基金 / 基金详情

Developmental research of new generation DNA vaccine against microorganism using synthesized DNA

Developmental research of new generation DNA vaccine against microorganism using synthesized DNA
利用合成DNA对抗微生物的新一代DNA疫苗的开发研究
批准号:
15390145
负责人:
OKUDA Kenji
金额:
$9.86万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2003
资助国家:
日本
项目状态:
已结题
起止时间:
2003 至 2004

项目摘要

项目成果

OKUDA Kenji的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
In this study, we studied the importance of preventive DNA vaccine and virus vector vaccine against microbe infectious diseases. We constructed three types of DNA vaccine of pseudomonas containing Opr F/I, Pcr V and Pill genes. After immunization to mice with each or the combination of DNA vaccine, the mice were challenged with D1 strain. When immunized with the combination of three vaccines, more than 90% of the mice were survived. The preventive effect was high in order of Pcr V, OprF/I and Pili. Non immunized mice died 2 days later after challenging. Therefore, the vaccines which we constructed have strong effects to prevent infection and we confirmed that Pcr V worked as strong preventive antigen.On the other hand, to observe preventive effects against HIV-1, we developed a new DNA vector which the genes of Gag-Pal and Env were inserted into CAG promoter and an E1 deficient adeno 5/35 virus vector which the fiber of adeno virus type 5 replaced into the fiber of adeno type35. After immunization using these novel vaccines, we challenged monkeys with SHIV89.6. At the group which were immunized with DNA vaccine+Ad5/35, the viral load kept under the detectable level up to 25th weeks. Former adeno virus vector of type 5 had some faults such as liver obstacle. However, it became clear that Ad5/35 vector was best for human.From these results, we are going to develop more convenient immunizing route of pseudomonas vaccine for clinical trial. On HIV-1, we are planning to join with some pharmaceutical companies to do phase I clinical trial. Furthermore, we hope to develop other best DNA vaccines or virus vector vaccines against severe infectious diseases such as O-157 or Ave influenza using Ad5/35 vector.
期刊论文(104)
专著(0)
科研奖励(0)
会议论文
Xin, K.Q.: "A DNA vaccine containing inverted terminal repeats from adeno-associated virus increases immunity to HIV."J.Gene Med.. 5. 438-445 (2003)
Xin, K.Q.:“含有腺相关病毒反向末端重复序列的 DNA 疫苗可增强对 HIV 的免疫力。”J.Gene Med.. 5. 438-445 (2003)
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Combination of DNA vaccine and adenovirus vector by cutaneous administration induced strong HIV-specific cellular immune responses in mice
DNA疫苗和腺病毒载体的组合通过皮肤给药在小鼠体内诱导了强烈的HIV特异性细胞免疫反应
DOI: --
发表时间: 2005
期刊: Vaccine 23
影响因子: --
作者: [Takakura, M., Okuda, K., Matsuda, T., Takeshita, F., Takakura, H., Ikezawa, Z, Xin, K.-Q.]
通讯作者: K.-Q.
DOI: --
发表时间: 2004
期刊: Biochem Biophys Res Commun 315
影响因子: --
作者: [Sasaki, S., Takeshita, F., Oikawa, T., Kojima, Y., Xin, K.-Q., Okuda, K., Ishii, N.]
通讯作者: N.
DOI: 10.1182/blood-2003-01-0110
发表时间: 2003-07-01
期刊: BLOOD
影响因子: 20.3
作者: [Xin, KQ, Hoshino, Y, Okuda, K]
通讯作者: Okuda, K
39
    Enhancement of protection against various microbial infection by the modification of dominance of Thl or Th2 immune responses
    • 批准号:
      11470070
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $9.79万
    • 财政年份:
      1999
    • 负责人:
      OKUDA Kenji
    • 依托单位:
    Study on the DNA immunization against microbial infection
    • 批准号:
      10044308
    • 项目类别:
      Grant-in-Aid for Scientific Research (C).
    • 资助金额:
      $1.73万
    • 财政年份:
      1998
    • 负责人:
      OKUDA Kenji
    • 依托单位:
    Roles of activation of antigen specific cytoxic T cells against micro bial infections.
    • 批准号:
      09670293
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $1.73万
    • 财政年份:
      1997
    • 负责人:
      OKUDA Kenji
    • 依托单位:
    海外基金